EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

[ 177 Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial

Nathalie L Albert, Emeline Tabouret, Emilie Le Rhun, Felix Sahm, Julia Furtner, Joerg-Christian Tonn, Christian Alfano, José Pais Silva, Anne-Sophie Govaerts, Thierry Gorlia, Osvaldo Mirante, Giuseppe Minniti und 3 weitere

Journal of Nuclear Medicine · 2026-01 · 67 (1) · 23-30

DOI: 10.2967/jnumed.125.269633 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 07.08.2025. Verfasst von Nathalie L Albert und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilians University, Munich, Germany; nathalie.albert@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Meningioma, Octreotide, Organometallic Compounds, Meningeal Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy. Somatostatin receptor type 2 (SSTR2) is highly expressed in meningiomas, and SSTR2-targeting radionuclide therapy with [177Lu]Lu-DOTATATE has shown potential activity in the treatment of meningioma in uncontrolled and small studies. Methods: EORTC-2334-BTG (LUMEN-1, NCT06326190) is a randomized, multicenter, phase II trial in patients with recurrent World Health Organization (WHO) grade 1, 2, or 3 meningioma. In total, 136 patients will be randomized in a 2:1 ratio to [177Lu]Lu-DOTATATE (≤4 doses of 7.4 GBq given every 4 wk) or local standard of care (hydroxyurea, bevacizumab, sunitinib, octreotide, everolimus, or observation). The main eligibility criteria include age 18 y or older; neuropathologically confirmed meningioma of WHO grade 1, 2, or 3; WHO performance score of 0-2; measurable disease on MRI (≥10 × 10 mm); radiologically documented progression of any existing tumor (growth > 25% or new lesions) or appearance of new lesions within the last 2 y; SSTR positivity by PET imaging (SUVmax > 2.3); at least 1 prior surgery and at least 1 line of radiotherapy; and no prior systemic therapy. The primary efficacy endpoint is locally assessed progression-free survival according to Response Assessment in Neuro-Oncology MRI meningioma criteria, and secondary endpoints include radiologic response rate, overall survival, safety, health-related quality of life, and neurologic function. The trial protocol includes a comprehensive exploratory translational research program with dosimetry and imaging-based and tissue-based investigations. LUMEN-1 was activated in March 2025 and will enroll patients in 35 sites in 10 countries across Europe, with primary endpoint collection planned after 2 y and study completion after 5 y. To our knowledge, EORTC-2334-BTG (LUMEN-1, NCT06326190) is the first prospective randomized trial investigating the efficacy of [177Lu]Lu-DOTATATE in patients with recurrent meningioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaOctreotideOrganometallic CompoundsMeningeal NeoplasmsNeoplasm Recurrence, LocalHumansRandomized Controlled Trials as TopicRecurrenceClinical Trials, Phase II as TopicReceptors, SomatostatinFemaleMaleAdult

Stichwörter der Autor:innen

[177Lu]Lu-DOTATATEclinical trialmeningiomaradiopharmaceutical therapytheranostic

Substanzen

Octreotidelutetium Lu 177 dotatateOrganometallic CompoundsReceptors, Somatostatin

Autor:innen und Institutionen

  • Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilians University, Munich, Germany; nathalie.albert@med.uni-muenchen.de.
  • APHM, Aix-Marseille University, CNRS, INP, Marseille, France.
  • Service de Neurooncologie, CHU Timone, Marseille, France.
  • Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland.
  • Department of Neuropathology, University Hospital Heidelberg and Clinical Cooperation Unit Neuropathology, DKFZ and DKTK, Heidelberg, Germany.
  • Research Center for Medical Image Analysis and Artificial Intelligence, Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria.

Zitieren

APA

Albert, N. L., Tabouret, E., Le Rhun, E., Sahm, F., Furtner, J., Tonn, J. C., Alfano, C., Silva, J. P., Govaerts, A. S., Gorlia, T., Mirante, O., Minniti, G., Weller, M., Preusser, M., & European Organisation for Research and Treatment of Cancer Brain Tumor Group (2026). [ 177 Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. Journal of Nuclear Medicine, 67(1), 23-30. https://doi.org/10.2967/jnumed.125.269633

Vancouver

Albert NL, Tabouret E, Le Rhun E, Sahm F, Furtner J, Tonn JC, et al. [ 177 Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. Journal of Nuclear Medicine. 2026;67(1):23-30. doi:10.2967/jnumed.125.269633

BibTeX
@article{Albert2026,
  author = {Albert, Nathalie L and Tabouret, Emeline and Le Rhun, Emilie and Sahm, Felix and Furtner, Julia and Tonn, Joerg-Christian and Alfano, Christian and Silva, José Pais and Govaerts, Anne-Sophie and Gorlia, Thierry and Mirante, Osvaldo and Minniti, Giuseppe and Weller, Michael and Preusser, Matthias and European Organisation for Research and Treatment of Cancer Brain Tumor Group, European Organisation for Research and Treatment of Cancer Brain Tumor Group},
  title = {[ 177 Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {1},
  pages = {23--30},
  doi = {10.2967/jnumed.125.269633}
}
Kostenlos starten →